License To Market Leukemia Service in Canada
By HospiMedica staff writers
Posted on 21 Aug 2007
Warnex (Laval, Canada) announced an exclusive license with Ipsogen SAS (Marseille, France) to market a service in Canada for the molecular diagnosis and classification of a group of leukemias.Posted on 21 Aug 2007
The service is based on the analysis of variations in the JAK2 gene, to which Ipsogen has exclusive worldwide intellectual property rights. A dominant gain-of-function V617F mutation in the JH2 kinase-like domain of JAK2A is present in a high proportion of patients with myeloproliferative disorders (MPD) such as polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.
The president and CEO of Ipsogen, Vincent Fert, said, The medical community is now eager to integrate the JAK2 test into clinical practice. Ipsogen has recently launched the test both in the form of a product and a licensing program to react rapidly to these urgent medical needs.
Mark Busgang, president and CEO of Warnex commented, In addition to expanding our service offering in medical testing, this license provides Warnex with the exclusivity for JAK2 clinical testing performed in Canada, thus significantly enhancing our market position. Finding the JAK2 mutation is a major step forward in diagnosing myeloproliferative disorders.
Related Links:
Warnex
Ipsogen SAS
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Blood Glucose Test Strip
AutoSense Test
New
Urine Chemistry Control
Dropper Urine Chemistry Control
